A detailed history of China Universal Asset Management Co., Ltd. transactions in Humacyte, Inc. stock. As of the latest transaction made, China Universal Asset Management Co., Ltd. holds 27,282 shares of HUMA stock, worth $106,672. This represents 0.01% of its overall portfolio holdings.

Number of Shares
27,282
Previous 22,955 18.85%
Holding current value
$106,672
Previous $124,000 10.48%
% of portfolio
0.01%
Previous 0.01%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Jan 23, 2025

BUY
$3.46 - $5.81 $14,971 - $25,139
4,327 Added 18.85%
27,282 $137,000
Q3 2024

Oct 25, 2024

BUY
$5.11 - $9.46 $45,811 - $84,808
8,965 Added 64.08%
22,955 $124,000
Q2 2024

Jul 19, 2024

SELL
$2.87 - $9.1 $16,912 - $53,626
-5,893 Reduced 29.64%
13,990 $67,000
Q1 2024

Apr 29, 2024

BUY
$2.57 - $4.84 $20,295 - $38,221
7,897 Added 65.89%
19,883 $62,000
Q4 2023

May 21, 2024

SELL
$1.99 - $3.12 $15,715 - $24,638
-7,897 Reduced 39.72%
11,986 $34,000
Q4 2023

Jan 23, 2024

BUY
$1.99 - $3.12 $18,556 - $29,094
9,325 Added 350.43%
11,986 $34,000
Q3 2023

May 21, 2024

BUY
$2.75 - $4.48 $3,591 - $5,850
1,306 Added 96.38%
2,661 $7,000
Q3 2023

Oct 30, 2023

BUY
$2.75 - $4.48 $3,591 - $5,850
1,306 Added 96.38%
2,661 $8,000
Q2 2023

May 21, 2024

SELL
$2.86 - $4.97 $122 - $213
-43 Reduced 3.08%
1,355 $3,000
Q2 2023

Jul 27, 2023

SELL
$2.86 - $4.97 $122 - $213
-43 Reduced 3.08%
1,355 $4,000
Q1 2023

May 21, 2024

BUY
$2.11 - $3.25 $740 - $1,140
351 Added 33.52%
1,398 $4,000
Q1 2023

Apr 27, 2023

BUY
$2.11 - $3.25 $740 - $1,140
351 Added 33.52%
1,398 $4,000
Q4 2022

May 21, 2024

SELL
$2.02 - $3.62 $38,048 - $68,186
-18,836 Reduced 94.73%
1,047 $2,000
Q4 2022

Jan 31, 2023

BUY
$2.02 - $3.62 $165 - $296
82 Added 8.5%
1,047 $2,000
Q3 2022

Oct 21, 2022

BUY
$1.22 - $5.14 $1,177 - $4,960
965 New
965 $3,000

Others Institutions Holding HUMA

About Humacyte, Inc.


  • Ticker HUMA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 103,007,000
  • Market Cap $403M
  • Description
  • Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular ...
More about HUMA
Track This Portfolio

Track China Universal Asset Management Co., Ltd. Portfolio

Follow China Universal Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.